ArticleNature2017
The whole-genome landscape of medulloblastoma subtypes.
Open access · hybridAbstract read
In one paragraph
Article in Nature, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 717 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
717citing papers in PubMed, 3 pooled it
54.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
717 citing papers in PubMed, 3 syntheses or guidelines pooled it, 1,165 citations in OpenAlex.
- Impact of molecular subtypes on postoperative hydrocephalus following resection of posterior fossa medulloblastoma and ependymoma in children: A systematic review and meta-analysis.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients.Cancer research · 2025Pooled it
- Systematic review and meta-analysis of bulk RNAseq studies in human Alzheimer's disease brain tissue.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition.Science advances · 2026Article
- Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency.Nature genetics · 2026Article
- CReP-mediated control of eIF2α phosphorylation is a critical node in MYC-driven medulloblastoma.Nature communications · 2026Article
- Clinical Outcomes and New Treatments in Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2026Article
- Molecular profiling of pediatric medulloblastoma in Kazakhstan: Genomic alterations, subgroup distribution, and survival.Brain pathology (Zurich, Switzerland) · 2026Article
- Cancer-associated KBTBD4 mutations induce differentiation defects and confer a unique therapeutic vulnerability.Cancer gene therapy · 2026Article
- Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup-specific prognostic stratification using economical/accessible diagnostic methods.Brain pathology (Zurich, Switzerland) · 2026Article
- Pediatric ependymoma in the molecular era: real-world experience with diagnostic correlation and long-term clinical outcomes.Journal of neuro-oncology · 2026Article
- Genome-wide DNA methylation analysis of pediatric medulloblastomas from a Brazilian cohort: an exploratory study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- 3D chromatin structure remodelling in cancer.Cell communication and signaling : CCS · 2026Review
- Differentially Methylated Regions in Human Rhombic Lip Compartments Are Enriched in Putative Active Enhancers, Human Accelerated Regions, and Medulloblastoma Copy Number Aberrations.Cerebellum (London, England) · 2026Article
- KIF14 silencing suppresses cell proliferation and enhances chemosensitivity by modulating 53BP1 nucleocytoplasmic shuttling in non-WNT/non-SHH medulloblastoma.Cell death discovery · 2026Article
- Therapeutic Potential of Targeting USP2 in Pediatric Group 3 and 4 Medulloblastomas: Insights from In Silico, Ex Vivo, and In Vitro Studies.Cerebellum (London, England) · 2026Article
- From developmental origins to relapse: molecular and therapeutic insights in medulloblastoma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Review
- Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model.Molecular oncology · 2026Article
- A Nationwide Central Diagnosis for Pediatric CNS Tumors in Japan: The JCCG Brain Tumor and Pathology Committees.Cancer science · 2026Article
- Protein phosphatase 2A regulates senescence and immunogenicity in medulloblastoma models.The Journal of clinical investigation · 2026Article
657 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
87 authors at 20 institutions in 7 countries.
Paul A NorthcottDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ivo BuchhalterDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
A Sorana MorrissyDevelopmental &Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario.
Volker HovestadtDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Joachim WeischenfeldtBiotech Research &Innovation Centre (BRIC), Copenhagen University and Finsen Laboratory, Rigshospitalet, Denmark.
Tobias EhrenbergerDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Susanne GröbnerDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Maia Segura-WangGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Thomas ZichnerGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Vasilisa A RudnevaGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Hans-Jörg WarnatzMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics, Berlin, Germany.
Nikos SidiropoulosBiotech Research &Innovation Centre (BRIC), Copenhagen University and Finsen Laboratory, Rigshospitalet, Denmark.
Aaron H PhillipsDepartment of Structural Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Steven SchumacherBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Kortine KleinheinzDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Sebastian M WaszakGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Serap ErkekDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
David T W JonesDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Barbara C WorstDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Marcel KoolDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Marc ZapatkaDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Natalie JägerDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lukas ChavezDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Barbara HutterDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matthias BiegDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Nagarajan ParamasivamDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael HeinoldDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Zuguang GuDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Naveed IshaqueDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Christina Jäger-SchmidtDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Charles D ImbuschDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Alke JugoldDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Daniel HübschmannDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Thomas RischMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics, Berlin, Germany.
Vyacheslav AmstislavskiyMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics, Berlin, Germany.
Francisco German Rodriguez GonzalezBiotech Research &Innovation Centre (BRIC), Copenhagen University and Finsen Laboratory, Rigshospitalet, Denmark.
Ursula D WeberDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stephan WolfGenomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Giles W RobinsonDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Xin ZhouDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Gang WuDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
David FinkelsteinDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Yanling LiuDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Florence M G CavalliDevelopmental &Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario.
Betty LuuDevelopmental &Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario.
Vijay RamaswamyDevelopmental &Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario.
Xiaochong WuDevelopmental &Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario.
Jan KosterDepartment of Oncogenomics, Amsterdam Medical Center, Amsterdam, Netherlands.
Marina RyzhovaDepartment of Neuropathology, NN Burdenko Neurosurgical Institute, Moscow, Russia.
Yoon-Jae ChoDepartment of Pediatrics, Papé Family Pediatric Research Institute, Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA.
Scott L PomeroyDepartment of Neurology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Christel Herold-MendeDepartment of Neurosurgery, University Clinic, Heidelberg University, Heidelberg Hospital, Germany.
Martin SchuhmannDepartment of Neurosurgery, University Hospital Tübingen, Tübingen, Germany.
Martin EbingerDepartment of Hematology and Oncology, Children's University Hospital Tübingen, Tübingen, Germany.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Jaume MoraDevelopmental Tumor Biology Laboratory, Hospital Sant Joan de Déu, Barcelona, Spain.
Roger E McLendonDepartment of Pathology, Duke University, Durham, North County, USA.
Nada JabadoDepartment of Pediatrics, McGill University, Montreal, Quebec, Canada.
Toshihiro KumabeDepartment of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan.
Eric ChuahMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Yussanne MaMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Richard A MooreMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Andrew J MungallMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Karen L MungallMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Nina ThiessenMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Kane TseMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Tina WongMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Steven J M JonesMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Olaf WittDepartment of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Till MildeDepartment of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Andreas Von DeimlingDepartment of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
David CapperDepartment of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Andrey KorshunovDepartment of Neuropathology, Heidelberg University Hospital, Heidelberg, Germany.
Marie-Laure YaspoMax Planck Institute for Molecular Genetics, Department of Vertebrate Genomics, Berlin, Germany.
Richard KriwackiDepartment of Structural Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Amar GajjarDepartment of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Jinghui ZhangDepartment of Computational Biology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Rameen BeroukhimBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Ernest FraenkelDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Jan O KorbelGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Benedikt BrorsDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matthias SchlesnerDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Roland EilsDivision of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Marco A MarraMichael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, British Columbia, Canada.
Stefan M PfisterDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michael D TaylorDevelopmental &Stem Cell Biology Program, The Hospital for Sick Children, Toronto, Ontario.
Peter LichterDivision of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DESt. Jude Children's Research Hospital · USEuropean Molecular Biology Laboratory · DEBC Cancer Agency · CACanada's Michael Smith Genome Sciences Centre · CAMax Planck Institute for Molecular Genetics · DEUniversity Hospital Heidelberg · DEBiologie du Développement et Cellules SouchesHospital for Sick Children · CABroad Institute · USMassachusetts Institute of Technology · USUniversity Children's Hospital Tübingen · DEUniversity of Copenhagen · DKBoston Children's Hospital · USBurdenko Neurosurgery Institute · RUCopenhagen University Hospital · DKDeutschen Konsortium für Translationale Krebsforschung · DEDuke University · USHospital Sant Joan de Déu Barcelona · ES
Funding
Mouse models to discover new drivers of medulloblastomaR01CA159859 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael D. Taylor, WILLIAM A WEISS · 2011 to 2026
$10.4MGENOMIC ANALYSIS OF MEDULLOBLASTOMASR01CA109467 · NCI · CHILDREN'S HOSPITAL BOSTON · PI MESIROV, JILL P., POMEROY, SCOTT LOREN · 2004 to 2015
$7.3MMedulloblastoma and MetastasesR01CA148699 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI TAYLOR, MICHAEL D., WEISS, WILLIAM A · 2010 to 2014
$2.4MNCI NIH HHS R01 CA109467NCI NIH HHS R01 CA148699NCI NIH HHS R01 CA159859
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and 'enhancer hijacking' events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma.
Indexed as
DNA Mutational AnalysisWhole Genome SequencingCarcinogenesisCarrier ProteinsCohort StudiesDatasets as TopicDNA MethylationEpistasis, GeneticGenome, HumanGenomicsHumansMedulloblastomaMolecular Targeted TherapyMuscle ProteinsMutationOncogenesCarrier ProteinsKBTBD4 protein, humanMuscle ProteinsPRDM6 protein, humanTranscription FactorsWnt Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.